Dr. Kantarjian receives Karnofsky Memorial Award
Hagop M. Kantarjian, M.D.
Department of Leukemia, Division of Cancer Medicine
About Dr. Kantarjian
Dr. Kantarjian is a professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, where he is also the Samsung Distinguished Leukemia Chair in Cancer Medicine. He is also a non-resident fellow in health policy at the Rice University Baker Institute.
Dr. Kantarjian has received several prestigious honors and awards including the 37th Jeffrey A Gottlieb Memorial Award (2012), the John Mendelsohn Lifetime Scientific Achievement Award (2008), the AACR Joseph H. Burchenal Memorial Award (2013),the Charles A. LeMaistre, M.D. Outstanding Achievement Award in Cancer (2014), and America’s Top Doctors, Castle Connolly Medical (2003-present). He was also selected the top Castle Connolly National Physician of the Year Award for Lifetime Achievement (2014). He received the ASCO David A. Karnofsky Memorial Award for lifelong contributions to leukemia research and patient care (2023).
Dr. Kantarjian’s research focuses on translational-clinical developmental therapeutics in leukemia. In the past four decades, he has made several contributions that improved prognosis and survival in patients with chronic myeloid leukemia (tyrosine kinase inhibitors, e.g. imatinib, dasatinib, nilotinib, bosutinib which improved the 10-year survival from 20% to 90%), in acute lymphocytic leukemia (HPER-CVAD regimen and its derivatives which improved cure rates from 20% to 60+%), the discovery of decitabine for the treatment of myelodysplastic syndrome, and of clofarabine for the treatment of leukemias, among others. His research and collaborations were the basis for the FDA approvals of over 20 drugs in leukemia. He is an author on over 2,400 peer-reviewed publications.
Present Title & Affiliation
Primary Appointment
Professor, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Samsung Distinguished University Chair in Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 1983 | The University of Texas MD Anderson Cancer Center, Houston, Texas, US, Hematology/Oncology, Medical Oncology Subspecialty |
| 1981 | American University of Beirut, Beirut, LB, Internal Medicine, Internal Medicine |
| 1979 | American University of Beirut, Beirut, LB, MD |
| 1975 | American University of Beirut, Beirut, LB, Science, BS |
| 1972 | American University of Beirut, Beirut, LB, BaccalaureateII |
Postgraduate Training
| 1980-1981 | Senior Resident, American University of Beirut, Beirut |
| 1979-1980 | Junior Resident, American University of Beirut, Beirut |
| 1978-1979 | Straight Intern, American University of Beirut, Beirut |
Licenses & Certifications
| 1990 | American Board of Hematology Certification |
| 1985 | American Board of Medical Oncology Certification |
| 1983 | American Board of Internal Medicine Certification |
Experience & Service
Faculty Academic Appointments
Kelcie Margaret Kana - Research Chair, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 1998 - 2015
Department Chair, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 1995 - 2025
Associate Professor, Department of Hematology, UT M.D. Anderson Cancer Center, Houston, TX, 1988 - 1993
Assistant Professor, Department of Hematology, UT M.D. Anderson Cancer Center, Houston, TX, 1984 - 1988
Faculty Associate, Department of Hematology, UT M.D. Anderson Cancer Center, Houston, TX, 1983 - 1984
Fellow, Department of Developmental Therapeutics, UT M.D. Anderson Cancer Center, Houston, TX, 1981 - 1983
Other Professional Positions
Board Liaison for the Cancer Communications Committee, ASCO, Houston, TX, 2015 - 2016
Education Subcommittee of the ASCO Board, ASCO, Houston, TX, 2015 - 2016
Member of the Audit Committee, ASCO, Houston, TX, 2015 - 2016
President, International Association for Comparative Research on Leukemia and Related Diseases (IACRLRD), Paris, 2015 - 2017
Fellow in Health Policy, Rice University's Baker Institute for Public Policy, Houston, TX, 2013 - 2015
Extramural Institutional Committee Activities
Committee Member, Global Academic Programs Steering Committee, The University of Texas MD Anderson Cancer Center, 2010 - Present
Committee Member, Chair Search, Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, 2007 - 2008
Chair, Subcommittee of the Faculty Achievement Award Parent Committee, The University of Texas MD Anderson Cancer Center, 2000
Committee Member, Physicians Referral Service Executive Council, The University of Texas MD Anderson Cancer Center, 1999 - Present
Co-Chair, Promotion and Tenure Committee, The University of Texas MD Anderson Cancer Center, 1999 - 2000
Chair, Search Committee, Department of Melanoma, The University of Texas MD Anderson Cancer Center, 1999 - 2000
Committee Member, Credentials Committee of the Medical Staff, The University of Texas MD Anderson Cancer Center, 1997 - 1998
Committee Member, Executive Committee of the Faculty Senate, The University of Texas MD Anderson Cancer Center, 1995 - Present
Vice Chairman, Surveillance Committee, The University of Texas MD Anderson Cancer Center, 1995 - 1996
Committee Member, Clinical Research Committee, The University of Texas MD Anderson Cancer Center, 1994 - Present
Committee Member, Search Committee for Director of Hematopathology, The University of Texas MD Anderson Cancer Center, 1994
Committee Member, Search Committee for Chairman, Department of Hematology, The University of Texas MD Anderson Cancer Center, 1993
Committee Member, Surveillance Committee, The University of Texas MD Anderson Cancer Center, 1992 - 1996
Alternate Member, Surveillance Committee, The University of Texas MD Anderson Cancer Center, 1991
Committee Member, Medical Record Committee, The University of Texas MD Anderson Cancer Center, 1988 - 1991
Alternate Member, Medical Record Committee, The University of Texas MD Anderson Cancer Center, 1987 - 1988
Committee Member, Nursing Liaison Committee, The University of Texas MD Anderson Cancer Center, 1987 - 1988
Committee Member, Research Committee, The University of Texas MD Anderson Cancer Center, 1986 - 1987
Committee Member, Infection Control Committee, The University of Texas MD Anderson Cancer Center, 1985 - 1986
Editorial Activities
Associate Editor-in-Chief, Acta haematologica, 2026 - Present
Associate Editor-in-Chief CML, Translational Leukemia Research and Therapy, 2026 - Present
Editorial Advisory Board, CANCER, CA: A Cancer Journal for Clinicians, 2024
Scientific Editor, Blood Cancer Discovery, 2019 - Present
Board Member, Clinical Key, 2017
Clinical Advisory Editor, Hematology/Oncology, 2015 - Present
International Advisory Board, The Lancet Haematology, 2014 - 2019
Associate Editor, In Practice Hodgkin Lymphoma, 2009 - Present
Editor, Clinica Lymphoma, Myeloma and Leukemia, 2009 - Present
Associate Editor, Journal of Clinical Oncology, 2008 - 2012
Editorial Board, Clinical Cancer Research, 2007 - 2015
Editorial Board, Clinical Advances in Hematology & Oncology, 2002
Editorial Board, Investigational New Drugs Journal, 2002
Editorial Board, Cancer, 2001 - Present
Associate Editor, Hematology, 1998 - Present
Editor, Journal of Clinical Oncology, 1998 - Present
Editorial Board, Journal of Clinical Oncology, 1998 - 2002
Associate Editor, Investigational New Drugs Journal, 1998 - 2001
Editorial Board, Leukemia and Lymphoma, 1995 - 2011
Unknown, Hematologic Pathology, 1993
Editorial Board, Journal of Clinical Oncology, 1990 - 1994
Unknown, Forum, 1990
Unknown, Bone Marrow Transplantation, 1990
Honors & Awards
| 2025 | Laureate for Special Distinction in Research, King Hussein Cancer Research Award 2025 |
| 2025 | The Richard Silver Award for Contribution to Leukemia Research, 25th Lymphoma, Leukemia & Myeloma Congress in New York, New York |
| 2025 | EHOG 2025 Lifetime Achievement Award, Eurasian Hematology Oncology Group |
| 2024 | R. Lee Clark Prize, The University of Texas MD Anderson Cancer Center |
| 2023 | Emil J Freireich Distinguished Pioneer Award Recipient, Society of Hematologic Oncology |
| 2023 | 2023 Inaugural Recipient-Emil J Freireich Distinguished Pioneer Award, Society of Hematology Oncology (SOHO) |
| 2023 | ASCO 2023 David Karnofsky Memorial Award and Lecture, American Society of Clinical Oncology |
| 2022 | Lifetime Achievement Award, Pfizer Hematology |
| 2020 | DoCM Excellence in Entrepreneurship Award, MD Anderson Cancer Center |
| 2019 - 2024 | MD Anderson Distinguished Educator, The University of Texas MD Anderson Cancer Center Academy of Health Science Education |
| 2019 | Doctor of Humane Letters honoris causa, American University of Beirut |
| 2018 - 2024 | H.J. Khoury Excellence in Research Award, 1st Annual Meeting of the International Academy for Clinical Hematology (IACH) |
| 2018 - 2024 | Fellow of the American Society of Clinical Oncology, American Society of Clinical Oncology |
| 2018 | 2018 Gerald P. Bodey, Sr., Distinguished Professorship Award, Bodey Professorship Committee. MD Anderson Cancer Center |
| 2018 | Officer-Medal of the Order of Cedars, Government of Lebanon |
| 2017 - 2024 | Honorary Professor, University of Jordan |
| 2016 - 2024 | Honorary Doctorate, Yerevan State Medical University |
| 2016 - 2024 | 7th Annual Lois F. O'Grady Distinguished Visiting Professor, UC Davis School of Medicine, Division of Hematology Oncology, Department of Internal Medicine |
| 2016 | Waun Ki Hong Award for Excellence in Team Science, 11th Annual MD Anderson Cancer Center, Division of Cancer Medicine, Faculty Recognition & Awards Program |
| 2016 | International CML Foundation John Goldman Prize-2016, International CML Foundation |
| 2015 | 2015 Lifetime Achievement Award, American Lebanese Medical Association |
| 2015 | 2015 President's Recognition, MD Anderson Cancer Center |
| 2014 - 2024 | Thomson Reuters Highly Cited Researcher, Thomson Reuters |
| 2014 | 2014 Castle Connolly National Physician of the Year Award for Lifetime Achievement, Castle Connolly Medical Ltd |
| 2014 | 2014 President's Recognition, MD Anderson Cancer Center |
| 2014 | 9th Annual Division of Cancer Medicine Faculty Recognition and Award Program. Waun Ki Hong Award for Excellence in Team Science, MD Anderson Cancer Center |
| 2014 | Charles A. LeMaistre, M.D. Outstanding Achievement Award in Cancer, The University of Texas MD Anderson Cancer Center |
| 2014 | 2014 Regents' Outstanding Teaching Award, The University of Texas Board of Regents |
| 2014 | Giants of Cancer Care Award, OncLive |
| 2014 | Lebanon Health Ministry Medal in Health Care Excellence, October 17 |
| 2013 - Present | Distinguished Alumnus, Hematology/Oncology Fellowship Program, The University of Texas MD Anderson Cancer Center |
| 2013 | 2013 Joseph H. Burchenal Memorial Award, American Association for Cancer Research |
| 2013 | Charles Koller, MD Lectureship Award, A Comprehensive Board Review in Hematology and Medical Oncology, MD Anderson Cancer Center |
| 2012 | Hematologic Malignancies 2012 Distinguished Lecturer Award, Houston, Texas, October |
| 2012 | 37th Jeffrey A Gottlieb Memorial Award |
| 2012 | AAAS Fellow, AAAS Council |
| 2012 | WAAAUB Distinguished Alumni Award, American University of Beirut |
| 2012 | Grinberg-Wisch Endowed Visiting Lectureship Award, Mount Sinai School of Medicine |
| 2012 | Top 1% of Physicians, US News and World Report |
| 2011 | Robert A. Kyle Award for Outstanding Clinician Scientist, Mayo Clinic |
| 2010 | Ben Qurrah Award |
| 2009 - 2010 | Best Doctors in America 2009-2010, Best Doctors |
| 2008 | The Division of Cancer Medicine, MD Anderson Cancer Center "John Mendelsohn Lifetime Scientific Achievement Award", MD Anderson Cancer Center |
| 2008 | The Division of Cancer Medicine, MD Anderson Cancer Center 'Waun Ki Hong Award for Excellence in Team Science", MD Anderson Cancer Center |
| 2006 | Schwartz Lectureship Award Recipient, Scripps Stevens Cancer Center |
| 2005 | Kenneth McCredie Memorial Lecture Award, International Association for Comparative Research on Leukemia and Related Diseases |
| 2003 - 2011 | America’s Top Doctors, Southwestern Region Top Hematologist, Castle Connolly Medical |
| 1999 | Faculty Achievement Award for Clinical Research, UT M.D. Anderson Cancer Center |
| 1999 | AUB Medical Alumni Gold Metal Award, The American University of Beirut Medical Center |
| 1998 - 2015 | Kelcie Margaret Kana Research Chair, UT M.D. Anderson Cancer Center |
| 1997 | First Emil J Freireich Award for Outstanding Clinical Research, UT M.D. Anderson Cancer Center |
| 1997 | Outstanding Service to Mankind Award, Leukemia Society of America |
| 1989 - 1994 | Scholar, Leukemia Society of America |
| 1985 - 1987 | Special Fellow, Leukemia Society of America |
| 1984 | Fellow, Leukemia Society of America |
| 1982 - 1983 | Fellow Research Award, UT M.D. Anderson Cancer Center |
| 1979 | Alpha Omega Alpha Honor Medical Society, American University of Beirut Chapter,Beirut, Lebanon |
| 1979 | Penrose Award |
| 1976 | Lange Award |
Professional Memberships
Selected Presentations & Talks
Formal Peers
- 2005. Is CML a curable malignancy without transplantation?. Invited. San Diego, CA, US.
- 2005. Insights into the molecular biology of acute leukemia & the implications for treatment. Invited. San Diego, CA, US.
- 2005. What is new in AML, MDS and CML. Invited. Cleveland, OH, US.
- 2004. Chronic myelogenous leukemia – what’s new. Invited, US.
- 2004. Novel approaches in AML and MDS. Invited. New York City, NY, US.
- 2004. Update on AML and MDS. Invited. New York City, NY, US.
- 2004. CML State of the Art. Invited. New York City, NY, US.
- 2002. A New Paradigm in the Treatment of CML. Invited. Hackensack, NJ, US.
- 2001. Understanding Myeloplastic Syndromes: A Primer for the Practicing Hematologist. Invited. Orlando, FL, US.
- 2001. Controversies in the Management of CML. Is Imatinib Mesylate or SCT the Therapy of Choice for De Novo CML Patients?. Invited. Orlando, FL, US.
- 2001. CML a New Treatment Paradigm, B-Cell Malignancies and Chronic Leukemias: Adances in Biology. Invited. Philadelphia, PA, US.
- 2001. Hematology/Medical Oncology Board Review, Chronic Myeloid Leukemia & Acute Lymphocytic Leukemia. Invited. Arlington, VA, US.
- 2001. Gleevec for CML. Invited, US.
- 2001. State of the art treatment in CML. Invited, US.
- 2001. Myelodysplasia, Challenging cases in hematology Pan Pacific Lymphoma Conference. Invited. Maui, HI, US.
- 2001. Challenging Cases in Malignant Lymphoma and Leukemia. Invited. Maui, HI, US.
- 2001. STI571 – Clinical results in Ph+ leukemias, Signal Transductions Inhibition (STI571): A New Standard in Oncology. Invited. San Francisco, CA, US.
- 2001. Acute Myeloid Leukemia -Victories, Deceptions, and Hopes. Fifth Middle East Oncology Congress. Invited. Beirut, LB.
- 1999. CML-Recent Advances. Invited. Corpus Christi, TX, US.
- 1999. Decitabine development by NCI/FDA. Invited. Bethesda, MD, US.
- 1999. 28th Annual Dr. William Dameshek Symposium, Update on Acute Leukemia. Invited. Wichita, KS, US.
- 1999. Adult Acute Lymphocytic Leukemia: Current Status and New Approaches. Invited. New York, NY, US.
- 1999. Investigational Strategies in Leukemia: How do we make progress?. Invited, US.
- 1998. CLL, ALL, CLL. Invited. Washington, US.
Grant & Contract Support
| Date: | 2025 - 2028 |
| Title: | Phase II Study of Cladribine Plus Idarubicin plus Cytarabine in Patients with AML, HR, MDS or Myeloid Blast Phase of CML; 2016-0979-FKAG-Ida-Ven; 2018-0020-Cladribine+Low Dose Ara-C+Venetoclax |
| Funding Source: | Tanoto Foundation Research |
| Role: | PI |
| ID: | 00017710 |
| Date: | 2023 - 2027 |
| Title: | Optimizing treatment decision by accounting for longitudinal biomarker trajectories and competing risks of each individual |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA272806-01A1 |
| Date: | 2020 - 2026 |
| Title: | Proposal for Leukemia Research and Training |
| Funding Source: | Marshall Legacy Foundation |
| Role: | PI |
| ID: | 00012316 |
Selected Publications
Peer-Reviewed Articles
- Short NJ, Kantarjian H, Daver N, Azevedo RS, Karrar O, DiNardo CD, Kadia T, Yilmaz M, Maroun M, Hachem M, Borthakur G, Issa GC, Shpall EJ, Popat U, Huang X, Qiao W, Nasr L, Macaron W, Abramova R, Garcia-Manero G, Konopleva M, Ravandi F. Long-term outcomes of azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML. Blood Adv 10(17):5743-5750, 2026. e-Pub 2026. PMID: 42200455.
- Beird HC, Kannan S, Liu J, Chen J, Olguin A, Desai P, Cai T, Han L, Cotton JL, Singh S, Gupta SK, Little L, Estecio MR, Song X, Abbas HA, Zhang J, Gumbs C, Brooks C, Kantarjian H, Andreeff M, Konopleva M, Futreal PA, Pemmaraju N. Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II. Leukemia 40(9):1951-1960, 2026. e-Pub 2026. PMID: 42410207.
- Azevedo RS, Jabbour E, Jain N, Haddad FG, Kebriaei P, Khouri I, Shpall EJ, Champlin R, Karrar O, Maroun M, Senapati J, Kugler E, Garris RS, Ravandi F, Kantarjian H, Short NJ. Predictors of survival in adults with B-cell acute lymphoblastic leukemia treated with blinatumomab and/or inotuzumab ozogamicin in first salvage. Leukemia 40(9):2008-2017, 2026. e-Pub 2026. PMID: 42463941.
- Kantarjian H, Deininger M, Apperley JF, Arthur CK, Chuah C, Hochhaus A, de Lavallade H, Lipton JH, Lomaia E, McCloskey J, Maness L, Mauro M, Moiraghi B, Pavlovsky C, Rosti G, Rousselot P, Chao B, Vorog A, Reddick LE, Patel N, Hennessy M, Yeh T, Cortes J. Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trial. Leukemia 40(9):1882-1892, 2026. e-Pub 2026. PMID: 42498834.
- Arora S, Senapati J, Chu V, Pemmaraju N, Bose P, Jabbour E, Kadia T, Ning J, Saenz D, Zhou L, Halim H, Alvarado Y, Ohanian M, DiNardo C, Takahashi K, Jain N, Ravandi F, Kantarjian H, Garcia-Manero G, Masarova L, Daver N. Final results of a phase II study of the combination of azacitidine and ruxolitinib in patients with myelofibrosis. Haematologica, 2026. e-Pub 2026. PMID: 42657929.
- Farhat A, El Hajjar G, Kantarjian H, Sasaki K, Short NJ, Cuglievan B, Loghavi S, Patel K, Bataller A, Jen WY, Yilmaz M, Montalban-Bravo G, Hammond D, Pemmaraju N, Daver N, Ravandi F, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G, DiNardo CD, Issa GC. Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia. Cancer 132(16):e70568, 2026. e-Pub 2026. PMID: 42590967.
- Kantarjian H, Jen WY, Kugler E, Garris R, Pierce S, Jain N, Short NJ, Khouri I, Loghavi S, Haddad FG, Ravandi F, Jabbour E. Results of second-line therapy in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 132(15):e70533, 2026. e-Pub 2026. PMID: 42482409.
- Issa GC, Cuglievan B, El Hajjar G, Jen WY, Bataller A, Short NJ, DiNardo CD, Alvarado Y, Loghavi S, Duose DY, Zhang B, Furudate K, Ning J, Xiao L, Mouhayar E, Pinto A, Bidikian A, Thompson E, Daver N, Garcia-Manero G, Farhat A, McCall D, Kadia TM, Abbas HA, Tan S, Bazinet A, Jabbour E, Montalban-Bravo G, Ravandi F, Takahashi K, Andreeff M, Kantarjian HM. All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE). J Clin Oncol 44(22):2110-2120, 2026. e-Pub 2026. PMID: 42272166.
- Jen WY, Jabbour E, Kugler E, Jain N, Garris R, Short NJ, Pierce S, Khouri I, Wang SA, Haddad F, Ravandi F, Kantarjian H. Results of Third-Line Therapy in Philadelphia Chromosome-Positive Adult Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 26(8):519-525, 2026. e-Pub 2026. PMID: 42392945.
- Kugler E, Ravandi F, Bazinet A, Dinardo CD, Daver N, Yilmaz M, Short NJ, Jen WY, Senapati J, Maiti A, Borthakur G, Garcia-Manero G, Kantarjian HM, Kadia TM. Relapse risk and survival benchmarks for non-transplanted acute myeloid leukemia patients in first complete remission. Haematologica, 2026. e-Pub 2026. PMID: 42489069.
- Topp MS, Shah BD, Jabbour E, Park JH, Shaughnessy P, Logan AC, Sandhu KS, Abedi M, Bishop MR, DeAngelo DJ, Yin X, Davi R, Hodby K, Malladi R, Brugger W, Shang J, Roddie C, Kantarjian HM. Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Leukemia, 2026. e-Pub 2026. PMID: 42469475.
- Lane AA, Luskin MR, Keating JH, LeBoeuf NR, Garcia JS, Shimony S, Leonard R, Goodpaster A, Nguyen T, Galinsky I, Eberly Puleo A, Daver NG, Jain N, Garcia-Manero G, Kantarjian HM, Konopleva M, Stein AS, Pemmaraju N. Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm. Blood, 2026. e-Pub 2026. PMID: 42413008.
- Htut TW, Kekedjian J, Short N, Bazinet A, Alvarado Y, Bataller A, Issa G, Borthakur G, Maiti A, Yilmaz M, Jain N, Masarova L, Chien K, Senapati J, Jabbour E, Montalban-Bravo G, Pierce S, DiNardo CD, Kadia T, Daver N, Konopleva M, Huang X, Kantarjian H, Garcia-Manero G, Ravandi F. Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia. Haematologica, 2026. e-Pub 2026. PMID: 42389833.
- Senapati J, Kantarjian HM, Ayoub E, Quesada AE, Loghavi S, Sasaki K, Kadia TM, Daver N, DiNardo CD, Jain A, McCabe M, Haddad FG, Brandt M, Tang G, Alvarado Y, Farish K, Abbas HA, Garcia-Manero G, Ravandi F, Andreeff M, Borthakur G. Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial. Blood Cancer Discov 7(4):572-585, 2026. e-Pub 2026. PMID: 41979452.
- Kadia TM, Bataller A, Bazinet A, Borthakur G, Daver N, Short NJ, DiNardo C, Jabbour E, Rausch CR, Issa GC, Pemmaraju N, Ohanian M, Maiti A, Montalban-Bravo G, Sasaki K, Bouligny IM, Yilmaz M, Haddad FG, Masarova L, Chien K, Alvarado Y, Jain N, Popat U, Shpall E, Loghavi S, Qiao W, Wang X, Garcia-Manero G, Ravandi F, Kantarjian HM. Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia. Am J Hematol 101(7):1737-1747, 2026. e-Pub 2026. PMID: 42035228.
- Jabbour E, Rausch CR, Goulart H, Jain N, Ravandi F, Maiti A, Alvarado Y, Burger J, Yilmaz M, Khouri I, Kebriaei P, Jorgensen J, Wang SA, Wang X, Mayor E, Garris RS, Short NJ, Kantarjian H. Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia. Blood Cancer J, 2026. e-Pub 2026. PMID: 42365008.
- Li J, Seetoh WS, Xu H, Tao Y, Liu M, Cai S, Lu J, Lu C. Mapping the research landscape of myelodysplastic syndromes: a scientometric analysis (2014-2025). Clin Exp Med, 2026. e-Pub 2026. PMID: 42350707.
- Nguyen D, Kantarjian HM, Bidikian A, Manuel CM, Qiao W, Ning J, DiNardo CD, Kadia TM, Daver N, Borthakur G, Jabbour E, Yilmaz M, Maiti A, Sasaki K, Montalban-Bravo G, Chien K, Hammond D, Pierce S, Andreeff M, Ravandi F, Short NJ, Garcia-Manero G, Issa GC. Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia. Clin Cancer Res, 2026. e-Pub 2026. PMID: 42329225.
- Jamison T, Jabbour E, Karrar O, Jain N, Haddad FG, Kebriaei P, Khouri I, Popat U, Yang H, Kugler E, Garris R, Garcia-Manero G, Kantarjian H, Short NJ. Latency between detectable low-level MRD by next-generation sequencing and overt relapse in ALL: implications for the optimal frequency of MRD monitoring. Leuk Lymphoma:1-4, 2026. e-Pub 2026. PMID: 42220306.
- Loghavi S, Farhat A, Jamison TJ, El Hajjar G, Bataller A, Wang SA, Wang W, Tang G, Quesada AE, Bazinet A, Cuglievan B, DiNardo CD, Montalban-Bravo G, Takahashi K, Short NJ, Abbas HA, Kadia T, Ravandi F, Daver N, Jabbour E, Borthakur G, Andreeff M, Medeiros LJ, Kantarjian HM, Issa GC. Immunophenotypic changes following menin inhibition in acute myeloid leukemia. Leukemia 40(6):1142-1150, 2026. e-Pub 2026. PMID: 41814014.
- Haddad FG, Kantarjian H. Chronic myeloid leukemia: incorporation of recent advances into current treatment algorithms. Blood Cancer J, 2026. e-Pub 2026. PMID: 42209462.
- Arora S, Kantarjian H, Sasaki K, Jain N, Li Z, Qiao W, Loghavi S, Tang G, Rausch C, Ravandi F, Haddad FG, Senapati J, Bravo GM, Bazinet A, Khouri R, Garris R, Garcia-Manero G, Short NJ, Jabbour E. Predictors of Relapse and Post-Relapse Outcomes After Frontline Blinatumomab in Philadelphia Chromosome-Negative B-ALL. Am J Hematol 101(8):2038-2043, 2026. e-Pub 2026. PMID: 42144287.
- Marvin-Peek J, DiNardo CD, Loghavi S, Ravandi F, Borthakur G, Daver NG, Kadia TM, Jabbour E, Dunbar A, Tang G, Short NJ, Haddad FG, Abbas HA, Kugler E, Maiti A, Issa GC, Takahashi K, Bhalla K, Pemmaraju N, Alvarado Y, Shpall EJ, Popat U, Ramdial J, Champlin RE, Kantarjian HM, Garcia-Manero G, Senapati J. Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy. Cancer 132(10):e70434, 2026. e-Pub 2026. PMID: 42089434.
- Montalban-Bravo G, Wu C, Rodriguez-Sevilla JJ, Wei Y, Chien KS, Bouligny I, Kanagal-Shamanna R, Li Z, Natu A, Gurney M, Bazinet A, Hammond D, Bataller A, Borthakur G, Short NJ, DiNardo CD, Kadia TM, Ravandi F, Daver N, Pemmaraju N, Jabbour E, Issa GC, Wang SA, Patel KP, Tang G, Medeiros LJ, Lasho TL, Finke CM, Al-Kali A, Csizmar CM, Alkhateeb H, Gangat N, Mangaonkar AA, Roman-Bravo D, Arenillas L, Tefferi A, Kantarjian HM, Garcia-Manero G, Calvo X, Patnaik MM, Loghavi S. Incorporation of Genomic Determinants Improves Diagnostic Accuracy of Oligomonocytic Chronic Myelomonocytic Leukemia. Blood Cancer Discov 7(3):414-430, 2026. e-Pub 2026. PMID: 41587375.
- Swaminathan M, Ferrajoli A, Thompson PA, Burger J, Borthakur G, Takahashi K, Estrov Z, Bharathi V, Bataller A, Kadia TM, Pemmaraju N, Daver N, Jabbour E, Bose P, Kanagal-Shamanna R, Patel KP, Wang SA, Garg N, Hwang H, Wang X, Qiao W, Xu X, Cruz N, Ayala A, Pierce S, Plunkett W, Sampath D, Kantarjian HM, Keating MJ, Gandhi V, Wierda WG, Jain N. Ibrutinib with Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: A Phase II Study. Blood Cancer Discov 7(3):431-440, 2026. e-Pub 2026. PMID: 41678768.
- Haddad FG, Jabbour E, Sasaki K, Black S, Savoy JM, Alvarado Y, Borthakur G, Pemmaraju N, Yilmaz M, Delasalla S, Issa GC, Kantarjian H. Outcomes of Patients Treated With Dasatinib 50 mg/d: A Pooled Analysis. Clin Lymphoma Myeloma Leuk 26(5):e678-e682.e1, 2026. e-Pub 2026. PMID: 41876352.
- Sasaki K, Kantarjian H, Rausch CR, Goulart H, Jain N, Huang X, Hachem M, Wierda WG, Kadia TM, Borthakur G, Issa GC, Alvarado Y, Pemmaraju N, Garris R, Ravandi F, Garcia-Manero G, Short NJ, Jabbour E. Blinatumomab and Ponatinib Versus Hyper-CVAD and Ponatinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Propensity Score Analysis. Am J Hematol 101(7):1717-1722, 2026. e-Pub 2026. PMID: 42031676.
- Kantarjian H, Qiao W, Jain N, Jen WY, Kugler E, Short NJ, Garris R, Pierce S, Kebriaei P, Wang SA, Haddad F, Ravandi F, Huang X, Jabbour E. Outcome of second-line therapy in adult B-cell acute lymphoblastic leukemia. Cancer 132(8):e70401, 2026. e-Pub 2026. PMID: 41954167.
- Pemmaraju N, Marconi G, Montesinos P, Lane AA, Mazzarella L, Sallman DA, Ulrickson ML, Schiller GJ, Erba HP, Wang ES, Walter RB, Deconinck E, Aribi A, Legrand O, Lebon D, Maisano V, Martinelli G, DeAngelo DJ, Derenzini E, Du Y, Lakshmikanthan S, Potluri J, Kantarjian HM, Daver NG. Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm. J Clin Oncol 44(10):861-873, 2026. e-Pub 2026. PMID: 41671533.
- Goulart H, Braish J, Short NJ, Jain N, Sasaki K, Kantarjian H, Jabbour EJ. A Case Report of Tyrosine Kinase Inhibitor Interruption in a Patient with Multilineage Philadelphia Positive Acute Lymphoblastic Leukemia. Acta Haematol:1-8, 2026. e-Pub 2026. PMID: 41915597.
- Bazinet A, Bataller A, Chien K, Sasaki K, Montalban-Bravo G, Hammond D, Bouligny I, Swaminathan M, Jen WY, Kugler E, Kanagal-Shamanna R, Kadia T, Borthakur G, DiNardo C, Short N, Pemmaraju N, Jabbour E, Daver N, Ravandi F, Urrutia S, Gener-Ricos G, Braish J, Briski R, Rodriguez-Sevilla JJ, Li Z, Champlin RE, Shpall EJ, Alousi A, Oran B, Hosing C, Ramdial JL, Olson A, Pierce S, Chen J, Kantarjian H, Garcia-Manero G, Popat U. Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes. Blood Cancer J 16(1), 2026. e-Pub 2026. PMID: 41896225.
- Nguyen D, Jabbour E, Kantarjian HM, Macaron W, Jain N, Nasnas C, Kebriaei P, Shpall EJ, Khouri I, Haddad F, Karrar O, Maroun M, Garris R, Ravandi F, Short NJ. Impact of high-sensitivity next-generation sequencing, measurable residual disease and subsequent stem cell transplant in patients receiving blinatumomab for MRD-positive B-cell acute lymphoblastic leukemia. Haematologica, 2026. e-Pub 2026. PMID: 41885010.
- Bazinet A, Ferrajoli A, Jain N, Burger JA, Yilmaz M, Swaminathan M, Kantarjian HM, Keating M, Thompson PA, Wierda WG. NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy. Blood Adv 10(12):4113-4116, 2026. e-Pub 2026. PMID: 41879712.
- Goulart H, Short NJ, Borthakur G, Jain N, DiNardo CD, Loghavi S, Khouri R, Hachem MCR, Ravandi F, Daver NG, Kadia TM, Yilmaz M, Issa GC, Bazinet A, Swaminathan M, Montalban-Bravo G, Haddad FG, Garris R, Kantarjian HM, Jabbour E. Mutations in Isocitrate Dehydrogenase Portend a Poor Prognosis in Adult Patients with Acute Lymphoblastic Leukemia. Blood Adv 10(9):3276-3280, 2026. e-Pub 2026. PMID: 41860396.
- Haddad FG, Jabbour EJ, Gutkin SW, Pathak AK, Zhai Y, Kantarjian HM. BCR::ABL1 Mutational Profiling in US Patients With Chronic-phase Chronic Myeloid Leukemia on Tyrosine Kinase Inhibitors. Cancer Diagn Progn 6(2):186-198, 2026. e-Pub 2026. PMID: 41778234.
- Haddad FG, Jabbour E, Chifotides HT, Sakkal S, Kantarjian H. Tyrosine kinase inhibitors, chronic myeloid leukemia, and pregnancy: pharmacotherapeutic challenges and recommendations. Expert Opin Pharmacother 27(4):311-318, 2026. e-Pub 2026. PMID: 41874348.
- DiNardo CD, Croden J, Abdel-Salam HM, Kadia T, Molica M, Bazinet A, Bose P, Maiti A, Haddad F, Burger J, Kantarjian H, Wierda W, Jain N, Ferrajoli A. Clinical, genetic, and familial features of POT1 tumor predisposition syndrome. Cancer 132(4):e70315, 2026. e-Pub 2026. PMID: 41686515.
- Turkalj S, Radtke FA, Stoilova B, Mecklenbrauck R, Groom AJ, Jakobsen NA, Lachowiez CA, Metzner M, Usukhbayar B, Salazar MA, Zeng Z, Loghavi S, Marvin-Peek J, Korber V, Ravandi F, Issa G, Kadia T, Symeonidou V, de Groot AP, Kantarjian H, Takahashi K, Konopleva M, DiNardo CD, Vyas P. Rapid clonal selection within early hematopoietic cell compartments presages the outcome of ivosidenib combination therapy. Blood 147(6):613-632, 2026. e-Pub 2026. PMID: 41191518.
- Chien KS, Loghavi S, Sasaki K, McCue D, Daver NG, Kadia TM, Ravandi F, Short NJ, Issa GC, Montalban-Bravo G, Haddad FG, Hammond DE, Swaminathan M, Bazinet A, Bataller A, Bouligny I, Pierce SA, Garcia-Manero G, Kantarjian HM, DiNardo CD. Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With Olutasidenib. Clin Lymphoma Myeloma Leuk 26(2):e223-e228.e3, 2026. e-Pub 2026. PMID: 41469316.
- Kadia TM, Jain A, Rausch CR, Bataller A, Ravandi F, Jabbour E, Qiao W, Borthakur G, Short N, Montalban-Bravo G, Quesada AE, Burger J, Ferrajoli A, Wierda W, Hosing C, Kantarjian H. Phase 1B pilot study of itacitinib with alemtuzumab in patients with T-cell prolymphocytic leukemia. Blood Neoplasia 3(1):100175, 2026. e-Pub 2026. PMID: 41536780.
- Senapati, J, Croden, J, Garcia-Manero, G, Takahashi, K, Daver, N, Kadia, TM, Borthakur, G, Short, NJ, Jabbour, EJ, Haddad, FG, Marvin-Peek, J, Abbas, HA, Bose, P, Tang, G, Loghavi, S, Shpall, E, Ramdial, JL, Popat, UR, Champlin, RE, Ravandi-Kashani, F, Kantarjian, HM, DiNardo, C. Outcomes of therapy-related non-core binding factor acute myeloid leukemia with venetoclax-based therapies. HemaSphere 10(2), 2026. e-Pub 2026. PMID: 41694734.
- Senapati J, Croden J, Garcia-Manero G, Takahashi K, Daver NG, Kadia TM, Borthakur G, Short NJ, Jabbour E, Haddad F, Marvin-Peek J, Abbas HA, Bose P, Tang G, Loghavi S, Shpall EJ, Ramdial J, Popat UR, Champlin RE, Ravandi F, Kantarjian HM, Dinardo CD. Outcomes of therapy-related non-core binding factor acute myeloid leukemia with venetoclax-based therapies. Hemasphere 10(2):e70317, 2026. e-Pub 2026. PMID: 41694734.
- Azevedo RS, Jabbour E, Kantarjian HM, Lavu S, Loghavi S, Jain N, Sasaki K, Garris RS, Takahashi K, Ravandi F, Short NJ. Impact of TP53 mutations and their variant allele frequency in adults with newly diagnosed acute lymphoblastic leukemia. Blood 147(5):547-556, 2026. e-Pub 2026. PMID: 41335402.
- Short NJ, Loghavi S, Yilmaz M, Karrar O, Kim K, Dinardo CD, Kadia TM, Maroun M, Borthakur G, Issa GC, Jabbour J, Oran B, Shpall EJ, Popat U, Patel KP, Routbort M, Konopleva M, Ravandi F, Kantarjian H, Daver N. Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor. Haematologica 111(4):1246-1253, 2026. e-Pub 2026. PMID: 41035402.
- Haddad, FG, Croden, J, Sasaki, K, Issa, GC, Pemmaraju, N, Kantarjian, HM, Jabbour, EJ. Management of Chronic Myeloid Leukemia During Pregnancy. Clinical Lymphoma, Myeloma and Leukemia 26(1):19-25, 2026. e-Pub 2026. PMID: 40883153.
- Braish, J, Kantarjian, HM, Short, NJ, Tang, G, Daver, N, Kadia, TM, Senapati, J, Jen, WY, Takahashi, K, Garris, R, Garcia-Manero, G, Ravandi-Kashani, F, Jabbour, EJ, Jain, N. Tyrosine Kinase Inhibitors During Frontline Therapy in Adults With Acute Lymphoblastic Leukemia With ABL-class Rearrangements. Clinical Lymphoma, Myeloma and Leukemia 26(1):e110-e113.e1, 2026. e-Pub 2026. PMID: 41125471.
- Bazinet A, Bataller A, Montalban-Bravo G, Chien K, Sasaki K, Jen WY, Swaminathan M, Kadia T, DiNardo C, Ravandi F, Garcia-Manero G, Kantarjian H. PTPN11 mutations define a rare but highly adverse subset of myelodysplastic syndromes. Haematologica 110(12):3125-3128, 2025. e-Pub 2025. PMID: 40605709.
- Jen WY, Tang G, Kugler E, Croden J, Sasaki K, Bazinet A, Bataller A, Montalban-Bravo G, Borthakur G, Toruner GA, Loghavi S, Short NJ, Issa GC, Bouligny IM, Pierce S, Popat U, Pemmaraju N, Jabbour E, Garcia-Manero G, Bhalla K, Ravandi F, Daver NG, DiNardo CD, Kantarjian HM, Kadia TM. MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia. Br J Haematol 207(6):2451-2461, 2025. e-Pub 2025. PMID: 40983567.
- Karrar O, Kantarjian H, Haddad FG, Azevedo RS, Issa G, Ravandi F, Sasaki K, Senapati J, Abbas H, Dellasala S, Jabbour E, Short NJ. Outcomes and patterns of relapse with ponatinib-based therapy in patients with chronic myeloid leukemia in myeloid blast phase. Leuk Lymphoma 66(12):2269-2276, 2025. e-Pub 2025. PMID: 40782369.
- Senapati J, Konopleva M, Issa GC, Jabbour E, Kadia T, DiNardo C, Borthakur G, Pemmaraju N, Short NJ, Yilmaz M, Deshmukh I, Alvarez J, Loghavi S, Tang G, Abbas HA, Andreeff M, Bhalla K, Midde NM, Said N, Noyalis A, Mires DE, Ning J, Xiao L, Ravandi F, Garcia-Manero G, Kantarjian HM, Daver NG. A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemias. J Hematol Oncol 18(1):108, 2025. e-Pub 2025. PMID: 41310838.
- Issa GC, Cai SF, Bataller A, Kantarjian HM, Stein EM. Combination Strategies with Menin Inhibitors for Acute Leukemia. Blood Cancer Discov 6(6):547-560, 2025. e-Pub 2025. PMID: 40900001.
- Kantarjian HM, Borthakur G, Daver N, DiNardo C, Garcia-Manero G, Issa G, Jabbour E, Jain N, Kadia T, Loghavi S, Ravandi F, Tang G, Welch MA, Wierda W. A tour of leukemia progress in 2025, viewed through the MD Anderson leukemia research lens. Cancer 131(21):e70113, 2025. e-Pub 2025. PMID: 41129068.
- Kantarjian H. Cytomolecular Mechanisms of Relapse and Post-Relapse Outcomes After Frontline FLT3 Inhibitor-Based Therapy in FLT3 -Mutated AML 100(11):2155-2159, 2025. e-Pub 2025. PMID: 40891194.
- Jen WY, Loghavi S, Bazinet A, Bataller A, Bouligny I, Daver NG, Issa GC, Arani N, Almanza Huante E, Maiti A, Montalban-Bravo G, Borthakur G, Short NJ, Pierce S, Jabbour E, Garcia-Manero G, Ravandi F, Kantarjian HM, DiNardo CD, Kadia TM. Outcomes and Patterns of Relapse of NPM1 Mutated Acute Myeloid Leukemia Treated With Venetoclax Based Therapies 100(11):2118-2122, 2025. e-Pub 2025. PMID: 40874710.
- Azevedo RS, Braish J, Gener-Ricos G, Tang G, Sasaki K, Montalban-Bravo G, Jabbour E, Ohanian M, Yilmaz M, Haddad FG, Chien K, Ishizawa J, Short NJ, Maiti A, Swaminathan M, Kantarjian H, Borthakur G, Kadia TM. Cladribine, high-dose cytarabine, plus gemtuzumab ozogamicin (CLAG-GO) as frontline intensive therapy for fit patients with core-binding factor acute myeloid leukemia. Leuk Lymphoma 67(1):1-5, 2025. e-Pub 2025. PMID: 41173347.
- Urrutia S, Sasaki K, Bataller A, Kantarjian HM, Montalban-Bravo G, McCloskey J, Griffiths EA, Yee KWL, Zeidan AM, Savona MR, Oganesian A, Sano Y, Keer HN, Garcia-Manero G. Decitabine-cedazuridine in patients with MDS and TP53 mutations. Blood Adv, 2025. e-Pub 2025. PMID: 41170912.
- Arani N, Rausch CR, Geppner A, Borthakur G, Jain N, Ferrajoli A, Jabbour E, Sampath D, Hosing C, Vega F, Kantarjian HM, Kadia TM. Cladribine and venetoclax combined with alemtuzumab in patients with relapsed/refractory T-cell prolymphocytic leukemia. Leuk Lymphoma:1-5, 2025. e-Pub 2025. PMID: 41124080.
- Short NJ, Jabbour E, Macaron W, Jain N, Haddad FG, Loghavi S, Kadia TM, Kebriaei P, Kugler E, Matthews J, Garris R, Ravandi F, Kantarjian H. Prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL. Blood Cancer J 15(1):169, 2025. e-Pub 2025. PMID: 41120271.
- Montalban-Bravo G, Loghavi S, Li Z, Chien K, Kanagal-Shamanna R, Bataller A, Natu A, Gurney M, Bazinet A, Hammond D, Sasaki K, Borthakur G, Swaminathan M, DiNardo C, Kadia T, Ravandi F, Daver N, Short N, Pemmaraju N, Issa G, Lasho TL, Finke CM, Al-Kali A, Csizmar C, Alkhateeb H, Gangat N, Mangaonkar AA, Bueso-Ramos C, Tefferi A, Kantarjian H, Garcia-Manero G, Patnaik MM. Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia. Blood Adv 9(19):5105-5117, 2025. e-Pub 2025. PMID: 40644618.
- Jen WY, Croden J, Almanza-Huante E, DiNardo C, Chien K, Hammond D, Qiao W, Alvarado Y, Masarova L, Quesada AE, Pierce S, Bataller A, Garcia-Manero G, Alousi A, Short N, Daver N, Ravandi F, Kantarjian H, Kadia TM. A Phase 2 study of CPX-351 in combination with venetoclax in patients with newly diagnosed high-risk acute myeloid leukemia. Hemasphere 9(10):e70214, 2025. e-Pub 2025. PMID: 41132245.
- Haddad FG, Kantarjian H, Senapati J, Jain N, Short NJ, Jabbour E. SOHO State of the Art Updates and Next Questions | Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Can Be Treated with Chemotherapy-Free Regimens without Transplant. Clin Lymphoma Myeloma Leuk 25(10):711-719, 2025. e-Pub 2025. PMID: 40683769.
- Bazinet A, Loghavi S, Wei Y, Bataller A, Sasaki K, Arani N, Darbaniyan F, Chien K, Hammond D, Bouligny I, Kanagal-Shamanna R, Thongon N, Tang G, Urrutia S, Kadia T, DiNardo C, Daver N, Short N, Issa G, Pemmaraju N, Jabbour E, Wang SA, Wang W, Borthakur G, Bueso-Ramos C, Ravandi F, Medeiros LJ, Kantarjian H, Garcia-Manero G, Montalban-Bravo G. Erythroid-predominant myelodysplastic neoplasms exhibit a distinct genomic landscape with poor outcomes after venetoclax-based therapy. Leukemia 39(9):2256-2265, 2025. e-Pub 2025. PMID: 40691503.
- Habib D, Jabbour E, Bataller A, Sasaki K, Tang G, Loghavi S, Li S, Senapati J, Short NJ, Jain N, Kantarjian H, Haddad FG. Inferior Outcomes in Acute Lymphoblastic Leukemia With Translocation (14;18). Clin Lymphoma Myeloma Leuk 25(9):672-675, 2025. e-Pub 2025. PMID: 40222876.
- Bataller A, Short NJ, Daver N, Yilmaz M, Kantarjian H, Ravandi F. Current Treatment Strategies for FLT3-Mutated Acute Myeloid Leukemia in Patients not Candidates for Intensive Chemotherapy. Curr Oncol Rep 27(9):1097-1105, 2025. e-Pub 2025. PMID: 40748523.
- Kantarjian H, Pui CH, Jabbour E. Acute lymphocytic leukaemia. Lancet 406(10506):950-962, 2025. e-Pub 2025. PMID: 40759141.
- Goulart H, Jabbour E, Short N, Jain N, Issa G, Atluri H, Bataller A, Kadia T, Daver N, DiNardo C, Garris R, Senapati J, Ravandi F, Kantarjian H. Contemporary Outcomes of Adults With Acute Lymphoblastic Leukemia With KMT2A Rearrangements Treated With Immunotherapy-Based Regimens. Am J Hematol 100(11):2128-2133, 2025. e-Pub 2025. PMID: 40862325.
- DiNardo CD, Marvin-Peek J, Loghavi S, Takahashi K, Issa GC, Jen WY, Daver NG, Reville PK, Short NJ, Sasaki K, Mullin JK, Bradley CA, Borthakur G, Maiti A, Alvarado Y, Pemmaraju N, Abbas HA, Hammond DE, Haddad F, Bravo GM, Chien KS, Yilmaz M, Kornblau SM, Jabbour E, Ravandi F, Kadia T, Garcia-Manero G, Konopleva MY, Kantarjian HM. Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML. J Clin Oncol 43(24):2692-2699, 2025. e-Pub 2025. PMID: 40513054.
- Arora S, Jen WY, Yilmaz M, Deshmukh I, Senapati J, Loghavi S, Issa GC, Short NJ, Kadia TM, DiNardo CD, Borthakur G, Jabbour J, Pemmaraju N, Andreeff M, Takahashi K, Bhalla K, Popat U, Shpall EJ, Oran B, Abbas HA, Garcia-Manero G, Ravandi F, Kantarjian H, Daver N. Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutation. Cancer 131(16):e70032, 2025. e-Pub 2025. PMID: 40782343.
- Senapati J, Kantarjian HM, Kadia TM, Kekedjian J, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Short NJ, Yilmaz M, Jain N, Pemmaraju N, Abbas HA, Issa GC, Maiti A, Bravo GM, Deshmukh I, Shpall E, Kebriaei P, Popat U, Loghavi S, Thakral B, Tang G, Haddad FG, Alvarado Y, Manero GG, Ravandi F. Contemporary outcomes of octa-nonagenarians with newly diagnosed acute myeloid leukemia. Cancer 131(16):e70028, 2025. e-Pub 2025. PMID: 40772501.
- Croden J, Jen WY, Marvin-Peek J, Xiao L, Bouligny IM, Loghavi S, Borthakur G, Daver NG, Abbas HA, Takahashi K, Sasaki K, Pemmaraju N, Short NJ, Hammond D, Jabbour E, Masarova L, Chien KS, Issa GC, Montalban-Bravo G, Yilmaz M, Maiti A, Alvarado-Valero Y, Garcia-Manero G, Ravandi F, Konopleva MY, Kantarjian HM, Kadia TM, DiNardo CD. Outcomes of adult patients with newly diagnosed IDH-mutated AML treated with intensive chemotherapy and venetoclax. Leukemia 39(10):2538-2541, 2025. e-Pub 2025. PMID: 40813623.
- Short NJ, Kantarjian HM, Jain N, Kadia TM, Senapati J, Haddad FG, Maroun MM, Sasaki K, Xiao L, Huang X, Karrar O, Abramova R, Zhao M, Garris R, Konopleva MY, Ravandi F, Jabbour E. Mini-Hyper-CVD plus Venetoclax and Navitoclax for Relapsed/Refractory Acute Lymphoblastic Leukemia. Blood Adv 10(1):25-28, 2025. e-Pub 2025. PMID: 40763277.
- Apperley JF, Milojkovic D, Cross NCP, Hjorth-Hansen H, Hochhaus A, Kantarjian H, Lipton JH, Malhotra H, Niederwieser D, Radich J, Rousselot P, Saussele S, Schiffer CA, Silver R, Soverini S, Stenke L, Turkina A, Casado LF, Castagnetti F, Cervantes F, Clark RE, Cortes J, Deininger M, Hughes TP, Janssen J, Jiang Q, Kim DW, Larson RA, Mahon FX, Mauro M, Mayer J, Nicolini FE, Pane F, Rea D, Richter J, Rosti G, Saglio G, Hehlmann R. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Leukemia 39(8):1797-1813, 2025. e-Pub 2025. PMID: 40646132.
- Kadia TM, Jen WY, Bataller A, Bazinet A, Borthakur G, Jabbour E, Qiao W, Short NJ, Takahashi K, Issa GC, DiNardo CD, Montalban-Bravo G, Pemmaraju N, Tran A, Bharathi V, Loghavi S, Alousi AM, Popat U, Daver NG, Ravandi F, Kantarjian HM. A Phase 2 Trial of CPX-351 Combined With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia. Am J Hematol 100(8):1365-1373, 2025. e-Pub 2025. PMID: 40401707.
- Haddad FG, Kantarjian H, Senapati J, Jain N, Short J, Jabbour E. Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Can Be Treated With Chemotherapy-Free Regimens Without Transplant. Clinical Lymphoma Myeloma and Leukemia, 2025.
- Kantarjian H, Breccia M, Haddad FG, Hehlmann R, Issa GC, Malhotra H, Nicolini FE, Sasaki K, Stenke L, Jabbour E. Management of chronic myeloid leukemia in 2025. Cancer 131(14):e35953, 2025. e-Pub 2025. PMID: 40616814.
- Haddad FG, Kantarjian H, Short NJ, Jain N, Senapati J, Ravandi F, Jabbour E. Incorporation of Immunotherapy Into Adult B-Cell Acute Lymphoblastic Leukemia Therapy. J Natl Compr Canc Netw 23(8), 2025. e-Pub 2025. PMID: 40659041.
- Kantarjian H, Aldoss I, Jabbour E. Management of Adult Acute Lymphoblastic Leukemia: A Review. JAMA Oncol 11(7):771-778, 2025. e-Pub 2025. PMID: 40310617.
- Jabbour E, Lussana F, Martinez-Sanchez P, Torrent A, Rifon JJ, Agrawal V, Tormo M, Cassaday RD, Cluzeau T, Huguet F, Papayannidis C, Hernandez-Rivas JM, Rijneveld A, Fleming S, Vucinic V, Boll B, Ikezoe T, Abdul-Hay M, Savoie ML, Schuh AC, Berthon C, Schwartz S, Chiaretti S, Yuda J, Miyazaki T, Gonzalez-Campos J, Chen Y, Wong H, Choudhry J, Zugmaier G, Guest E, Gordon P, Kantarjian H. Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trial. Lancet Haematol 12(7):e529-e541, 2025. e-Pub 2025. PMID: 40532723.
- Bataller A, Goulart HE, Issa GC, DiNardo CD, Daver N, Kadia T, Bazinet A, Bouligny IM, Senapati J, Haddad FG, Borthakur G, Sasaki K, Short NJ, Yilmaz M, Montalban-Bravo G, Tang G, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian H, Jabbour E. Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements. Leukemia 39(7):1640-1649, 2025. e-Pub 2025. PMID: 40346311.
- Kantarjian H, Jabbour E. Adult Acute Lymphoblastic Leukemia: 2025 Update on Diagnosis, Therapy, and Monitoring. Am J Hematol 100(7):1205-1231, 2025. e-Pub 2025. PMID: 40377367.
- Uryu H, Saeki K, Haeno H, Kapadia CD, Furudate K, Nangalia J, Spencer Chapman M, Zhao L, Hsu JI, Zhao C, Chen S, Tanaka T, Li Z, Ogata S, Hanache S, Yang H, DiNardo C, Daver N, Pemmaraju N, Jain N, Ravandi F, Zhang J, Song X, Thompson E, Tang H, Little L, Gumbs C, Orlowski RZ, Qazilbash M, Bhalla K, Colla S, Kantarjian H, Kanagal-Shamanna R, Bueso-Ramos C, Nakada D, Al-Atrash G, Molldrem J, Futreal PA, Shpall E, Goodell M, Garcia-Manero G, Takahashi K. Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation. Nat Genet 57(7):1695-1707, 2025. e-Pub 2025. PMID: 40596442.
- Sallman DA, Komrokji RS, Dezern AE, Sebert M, Garcia-Manero G, Rahme R, Winer ES, Lehmann-Che J, Roboz GJ, Madelaine I, Sekeres MA, Peterlin P, Chan O, Beyne-Rauzy O, Kuykendall A, Recher C, McLemore A, Stamatoullas A, Zhang L, Willems L, Mo Q, Raffoux E, Nardelli L, Berthon C, Al Ali NH, Quesnel B, Padron E, Kantarjian HM, List AF, Ades L, Lancet JE, Fenaux P, Cluzeau T. Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML. HemaSphere 9(7):e70164, 2025. e-Pub 2025. PMID: 40657305.
- Croden J, Pemmaraju N, Fliehler K, Brown A, Wang W, Kantarjian H, Vega F, Kadia T. Managing BPDCN in the context of severe hyperbilirubinemia: a case study. Leuk Lymphoma:1-4, 2025. e-Pub 2025. PMID: 40569706.
- Azevedo RS, Jen WY, Hammond D, Haddad FG, Geppner A, Issa GC, Sasaki K, Senapati J, Jabbour E, Ravandi F, Kantarjian H, Kadia TM. Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with BCR::ABL1-negative B-cell / myeloid mixed phenotype acute leukemia. Haematologica 110(12):3129-3132, 2025. e-Pub 2025. PMID: 40568715.
- Csizmar CM, Natu A, Gurney M, Fathima S, Alsugair AKA, Kanagal-Shamanna R, Loghavi S, Bazinet A, Chien K, Hammond D, DiNardo C, Kadia T, Ravandi-Kashani F, Pemmaraju N, Sasaki K, Lasho TL, Finke CM, Al-Kali A, Alkhateeb H, Begna K, Gangat N, Hefazi Torghabeh M, Matin A, Mangaonkar AA, Saliba AN, Tefferi A, Garcia-Manero G, Kantarjian HM, Komrokji RS, Xie Z, Ali NA, Sallman D, Padron E, Montalban-Bravo G, Patnaik MM. Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypes. Leukemia 39(8):2030-2034, 2025. e-Pub 2025. PMID: 40555734.
- Reville PK, Wang B, Marvin-Peek J, Yuan B, Kuo YA, Garza A, Root J, Qiao W, Arruda A, Veletic I, Liu Y, Short NJ, DiNardo CD, Kadia TM, Daver NG, Lorenzi PL, Sasaki K, Kornblau S, Minden MD, Ravandi F, Kantarjian HM, Abbas HA. Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes. Blood 145(25):3015-3029, 2025. e-Pub 2025. PMID: 40179376.
- Daver N, Senapati J, Kantarjian HM, Wang B, Reville PK, Loghavi S, Yilmaz M, DiNardo CD, Kadia TM, Yassouf MY, Maiti A, Arora S, Montalban Bravo G, Tang G, Borthakur G, Sasaki K, Pemmaraju N, Alvarez J, Nogueras Gonzalez GM, Ning J, Issa GC, Konopleva M, Andreeff M, Ravandi F, Garcia-Manero G, Abbas HA. Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis. Clin Cancer Res 31(12):2386-2398, 2025. e-Pub 2025. PMID: 40198272.
- Lontos K, Saliba RM, Kanagal-Shamanna R, Ozcan G, Ramdial J, Chen G, Kadia T, Short NJ, Daver NG, Kantarjian H, Marin D, Kebriaei P, Popat U, Champlin R, Shpall E, Oran B. TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantation. Blood Adv 9(11):2845-2854, 2025. e-Pub 2025. PMID: 39853269.
- Senapati J, Loghavi S, Garcia-Manero G, Tang G, Kadia T, Short NJ, Abbas HA, Arani N, DiNardo CD, Borthakur G, Pemmaraju N, Oran B, Shpall E, Popat U, Champlin R, Pierce S, Arora S, Issa G, Yilmaz M, Patel K, Takahashi K, Montalban-Bravo G, Hammond D, Haddad FG, Ravandi F, Kantarjian HM, Daver NG. Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms. Haematologica 110(6):1304-1315, 2025. e-Pub 2025. PMID: 39665206.
- Senapati J, Kantarjian H, Habib D, Haddad FG, Jain N, Short NJ, Jabbour E. Frontline immunotherapeutic combination strategies in adult B-cell acute lymphoblastic leukemia: reducing chemotherapy intensity and toxicity and harnessing efficacy. Leuk Lymphoma 66(6):989-1000, 2025. e-Pub 2025. PMID: 39791458.
- Jabbour E, Haddad FG, Kantarjian H. Treatment of Older Patients With ALL. Am Soc Clin Oncol Educ Book 45(3):e473298, 2025. e-Pub 2025. PMID: 40354595.
- Kantarjian, HM, Jain, N, Litzow, M, Luger, SM, Papayannidis, C, Ribera, JM, Short, NJ, Chifotides, H, Jabbour, EJ. The evolving therapeutic revolution in adult acute lymphoblastic leukemia. Cancer 131(10), 2025. e-Pub 2025. PMID: 40323723.
- Short NJ, Kantarjian H, Furudate K, Jain N, Ravandi F, Karrar O, Loghavi S, Nasr L, Haddad FG, Senapati J, Garris R, Takahashi K, Jabbour E. Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab. J Hematol Oncol 18(1):55, 2025. e-Pub 2025. PMID: 40369607.
- Ravandi F, Rangaraju S, Kantarjian H, Garcia-Manero G, Yilmaz M, Baker K, Hall T, Grabenstein J, Roy P, Zamboni BA, Zamboni WC, Warlick E, Kelly M, Roth DA, Ghiaur G. A pharmacokinetic and safety study of oral arsenic trioxide in patients with acute promyelocytic leukemia. Blood Adv 9(9):2136-2143, 2025. e-Pub 2025. PMID: 40020161.
- Sasaki K, Garcia-Manero G, Nigo M, Jabbour E, Ravandi F, Wierda WG, Jain N, Takahashi K, Montalban-Bravo G, Daver NG, Thompson PA, Pemmaraju N, Kontoyiannis DP, Sato J, Karimaghaei S, Soltysiak KA, Raad II, Kantarjian HM, Carter BW. Artificial Intelligence Assessment of Chest Radiographs for COVID-19. Clin Lymphoma Myeloma Leuk 25(5):319-327, 2025. e-Pub 2025. PMID: 39710565.
- Jabbour EJ, Rousselot P, Gokbuget N, Chevallier P, Kantarjian HM, Stelljes M. Inotuzumab Ozogamicin as First-Line Therapy in Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 25(5):e302-e309, 2025. e-Pub 2025. PMID: 39909815.
- Senapati J, Loghavi S, Marvin-Peek J, Garcia-Manero G, Kadia TM, Borthakur G, Daver N, Short NJ, Jain N, Issa GC, Haddad F, Hammond D, Chien K, Tang G, Thakral B, Montalban-Bravo G, Pemmaraju N, Bazinet A, Swaminathan M, Pierce S, Abbas HA, Reville P, Popat U, Shpall E, Champlin R, Jabbour E, Ravandi F, Kantarjian HM, DiNardo CD. Clinico-Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies. Am J Hematol 100(5):758-769, 2025. e-Pub 2025. PMID: 39921561.
- Zhou T, Short NJ, Jain N, Patel KP, Jabbour EJ, Kantarjian HM, Medeiros LJ, Iorgulescu JB. Age-related prognoses of genetic subtypes in B-cell acute lymphoblastic leukemia/lymphoma (B-ALL): insights from a decade of national data. Leukemia 39(7):1769-1772, 2025. e-Pub 2025. PMID: 40275068.
- Willekens C, Bazinet A, Chraibi S, Bataller A, Decroocq J, Arani N, Carpentier B, Rausch C, Lebon D, Maiti A, Gauthier N, Short N, Bonnet S, Sasaki K, Khalife-Hachem S, Swaminathan M, Micol JB, Pasquier F, Marzac C, Roos-Weil D, Pascal L, Daver N, Kadia T, Bouscary D, Ravandi F, Pages A, Kantarjian H, De Botton S, DiNardo C. Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients. Blood Cancer J 15(1):68, 2025. e-Pub 2025. PMID: 40246832.
- Shen Q, Haddad FG, Jabbour EJ, Tang G, Fang H, Liu M, Hu AY, Wang W, Lin P, Issa GC, Kantarjian HM, Medeiros LJ, Hu S. Unusually Indolent CML: Absence of Complete Cytogenetic Response after 10 Years of Tyrosine Kinase Inhibitor Therapy. Clin Lymphoma Myeloma Leuk 25(8):e580-e590, 2025. e-Pub 2025. PMID: 40345959.
- Kantarjian H, Zhai Y, Oehler VG, Jamy O, Koller PB, Haddad FG, Sasaki K, Jabbour EJ. Olverembatinib in chronic myeloid leukemia-Review of historical development, current status, and future research. Cancer 131(8):e35832, 2025. e-Pub 2025. PMID: 40197896.
- Goulart H, Kantarjian H, Borthakur G, Daver N, DiNardo CD, Jabbour E, Pemmaraju N, Alvarado Y, Atluri H, Yilmaz M, Haddad FG, Marx KR, Rausch C, Loghavi S, Jain N, Garcia-Manero G, Ravandi-Kashani F, Kadia TM. Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trial. Cancer 131(8):e35840, 2025. e-Pub 2025. PMID: 40193193.
- Braish JS, Montalban-Bravo G, Ravandi F, Short N, Kadia T, Ohanian M, Chien K, Masarova L, Sasaki K, Yilmaz M, Logahvi S, Daver N, Borthakur G, Jabbour E, Schneider H, Romero LT, Kantarjian H, Garcia-Manero G. Safety and efficacy of the combination of azacitidine with venetoclax after hypomethylating agent failure in higher-risk myelodysplastic syndrome. Leuk Res 153:107692, 2025. e-Pub 2025. PMID: 40252309.
- Chien KS, Braish JS, Li Z, Loghavi S, Bataller A, Montalban-Bravo G, Sasaki K, Kanagal-Shamanna R, Takahashi K, DiNardo CD, Swaminathan M, Kantarjian HM, Garcia-Manero G. Clinicopathologic characteristics and outcomes of patients with clonal hematopoiesis who progress to myeloid neoplasms. Leukemia 39(5):1269-1272, 2025. e-Pub 2025. PMID: 40175627.
- DiNardo CD, Jen WY, Takahashi K, Kadia TM, Loghavi S, Daver NG, Xiao L, Reville PK, Issa GC, Short NJ, Sasaki K, Wang SA, Mullin JK, Pierce S, Bradley C, Borthakur G, Maiti A, Alvarado Y, Pemmaraju N, Ferrajoli A, Swaminathan M, Ohanian M, Abbas HA, Hammond D, Burger J, Haddad F, Montalban-Bravo G, Chien K, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia. Leukemia 39(4):854-863, 2025. e-Pub 2025. PMID: 40000842.
- Senapati J, Kadia TM, Daver NG, DiNardo CD, Borthakur G, Ravandi F, Kantarjian HM. Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges. Cancer 131(7):e35806, 2025. e-Pub 2025. PMID: 40105906.
- Haddad FG, Sasaki K, Senapati J, Hu S, Dellasala S, Issa GC, Jabbour E, Kantarjian H. Successful Treatment-Free Remission After Ponatinib Discontinuation in Pretreated Patients with Chronic Myeloid Leukemia in Chronic Phase. Clin Lymphoma Myeloma Leuk 25(4):254-257, 2025. e-Pub 2025. PMID: 39592322.
- Bataller A, Sasaki K, Urrutia S, Montalban-Bravo G, Bazinet A, Chien K, Hammond D, Bouligny IM, Swaminathan M, Issa G, Short N, Daver N, DiNardo CD, Kadia T, Jabbour E, Ravandi F, Roboz GJ, Savona M, Griffiths EA, McCloskey J, Odenike O, Oganesian A, Keer HN, Azab M, Kantarjian H, Garcia-Manero G. Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study. Blood Cancer J 15(1):50, 2025. e-Pub 2025. PMID: 40164584.
- Jabbour E, Kantarjian H. Chronic Myeloid Leukemia: A Review. JAMA 333(18):1618-1629, 2025. e-Pub 2025. PMID: 40094679.
- Bazinet A, Bataller A, Kadia T, Daver N, Short NJ, Yilmaz M, Sasaki K, DiNardo CD, Borthakur GM, Issa G, Bouligny I, Pierce S, Garcia-Manero G, Ravandi F, Kantarjian HM. A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia. Cancer 131(6):e35813, 2025. e-Pub 2025. PMID: 40097915.
- Kugler E, Kantarjian H, Jabbour E, Khaire N, Short NJ, Kadia TM, Haddad FG, Sasaki K, Kanagal Shamanna R, Garris R, Ravandi F, Jain N. Treatment-free remission in nontransplanted patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 131(5):e35773, 2025. e-Pub 2025. PMID: 39980368.
- Kantarjian, HM, Short, NJ, Jain, N, Haddad, FG, Kadia, TM, Yilmaz, M, Ferrajoli, A, Sasaki, K, Alvarado, Y, Pemmaraju, N, Senapati, J, Garris, R, Ravandi-Kashani, F, Jabbour, EJ. Hyper-CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. American journal of hematology 100(3):402-407, 2025. e-Pub 2025. PMID: 39757533.
- Paul S, Jabbour E, Nichols ED, Short NJ, Kantarjian H. Blinatumomab for the treatment of acute lymphoblastic leukemia in a real-world setting: clinical vignettes. Leuk Lymphoma 66(3):389-399, 2025. e-Pub 2025. PMID: 39611241.
- Kantarjian H, Short NJ, Jain N, Haddad FG, Kadia T, Yilmaz M, Ferrajoli A, Sasaki K, Alvarado Y, Pemmaraju N, Senapati J, Garris R, Ravandi F, Jabbour E. Hyper-CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Am J Hematol 100(3):402-407, 2025. e-Pub 2025. PMID: 39757533.
- Jen WY, Sasaki K, Ravandi F, Kadia TM, Wang SA, Wang W, Loghavi S, Daver NG, DiNardo CD, Issa GC, Abbas HA, Nasnas C, Bataller A, Urrutia S, Karrar OS, Pierce S, Kantarjian HM, Short NJ. Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy. Blood Adv 9(4):783-792, 2025. e-Pub 2025. PMID: 39631072.
- Senapati, J, Kantarjian, HM, Haddad, FG, Short, NJ, Borthakur, G, Kanagal Shamanna, R, Tang, G, Jabbour, EJ, DiNardo, C, Daver, N, Montalban Bravo, G, Shah, V, Alousi, AM, Shpall, E, Popat, UR, Garcia-Manero, G, Ravandi-Kashani, F, Kadia, TM. Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia. American journal of hematology 100(2):249-259, 2025. e-Pub 2025. PMID: 39718824.
- Senapati J, Kantarjian HM, Haddad FG, Short NJ, Borthakur G, Kanagal-Shamanna R, Tang G, Jabbour E, DiNardo CD, Daver N, Montalban-Bravo G, Shah V, Alousi A, Shpall E, Popat U, Garcia-Manero G, Ravandi F, Kadia TM. Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High-Risk Subtype That Warrants an Independent Prognostic Designation. Am J Hematol 100(2):249-259, 2025. e-Pub 2025. PMID: 39718824.
- Jabbour E, Oehler VG, Koller PB, Jamy O, Lomaia E, Hunter AM, Uspenskaya O, Samarina S, Mukherjee S, Cortes JE, Baer MR, Zherebtsova V, Shuvaev V, Turkina A, Davydkin I, Guo H, Chen Z, Fu T, Jiang L, Wang C, Wang H, Yang D, Zhai Y, Kantarjian H. Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. JAMA Oncol 11(1):28-35, 2025. e-Pub 2025. PMID: 39570620.
Review Articles
- DeAngelo DJ, Chen Y, Cassaday RD, Hibma JE, Yang DZ, Garrett M, Zhang F, Dimitrov SH, Vandendries ER, Kantarjian HM. Dose optimization of single-agent inotuzumab ozogamicin in adults with relapsed/refractory acute lymphoblastic leukemia. Leuk Lymphoma:1-11, 2026. e-Pub 2026. PMID: 42611806.
- Jabbour E, Kantarjian H. Adult acute lymphoblastic leukemia: incorporation of recent advances into current treatment strategies. Blood Cancer J, 2026. e-Pub 2026. PMID: 42401567.
- Macaron W, Kantarjian H, Jabbour E, Short NJ. SOHO State of the Art Updates and Next Questions | Management of High-Risk Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 26(7):409-418, 2026. e-Pub 2026. PMID: 42173720.
- Hochhaus A, Talpaz M, Saglio G, Cortes JE, Hughes T, Apperley J, Hantschel O, Rea D, Schuld P, Kantarjian H. From fatal disease to functional cure: 25 years of tyrosine kinase inhibition in chronic myeloid leukemia. Leukemia 40(6):1092-1110, 2026. e-Pub 2026. PMID: 42174092.
- Kantarjian H, Chifotides HT, Haddad FG, Jabbour E, Jain N, Kadia T, Ravandi F, Welch MA, Wierda W, Freireich EJ. The Care and Cure of the Leukemias in 2026. Am J Hematol 101(4):807-831, 2026. e-Pub 2026. PMID: 41761287.
- Haddad FG, Jabbour E, Breccia M, Hehlmann R, Malhotra H, Nicolini FE, Stenke L, Kantarjian H. SOHO State of the Art Updates and Next Questions | Choosing the Best Frontline BCR::ABL1 Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia-How to Define the Treatment Value?. Clin Lymphoma Myeloma Leuk 26(2):57-65, 2026. e-Pub 2026. PMID: 41139562.
Other Articles
- Issa GC, Cuglievan B, El Hajjar G, Jen WY, Bataller A, Short NJ, DiNardo CD, Alvarado Y, Loghavi S, Duose DY, Zhang B, Furudate K, Ning J, Xiao L, Mouhayar E, Pinto A, Bidikian A, Thompson E, Daver N, Garcia-Manero G, Farhat A, McCall D, Kadia TM, Abbas HA, Tan S, Bazinet A, Jabbour E, Montalban-Bravo G, Ravandi F, Takahashi K, Andreeff M, Kantarjian HM Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE). J Clin Oncol:JCO2601743, 2026. PMID: 42492014.
- DiNardo CD, Jen WY, Takahashi K, Kadia TM, Loghavi S, Daver NG, Xiao L, Reville PK, Issa GC, Short NJ, Sasaki K, Wang SA, Mullin JK, Pierce S, Bradley C, Borthakur G, Maiti A, Alvarado Y, Pemmaraju N, Ferrajoli A, Swaminathan M, Ohanian M, Abbas HA, Hammond D, Burger J, Haddad F, Montalban-Bravo G, Chien K, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia. Leukemia, 2025. PMID: 41372600.
- Uryu H, Saeki K, Haeno H, Kapadia CD, Furudate K, Nangalia J, Spencer Chapman M, Zhang L, Padilla J, Zhao L, Hsu JI, Zhao C, Chen S, Tanaka T, Li Z, Ogata S, Hanache S, Yang H, DiNardo C, Daver N, Pemmaraju N, Jain N, Ravandi F, Zhang J, Song X, Thompson E, Tang H, Little L, Gumbs C, Orlowski RZ, Qazilbash M, Bhalla K, Colla S, Kantarjian H, Kanagal-Shamanna R, Bueso-Ramos C, Nakada D, Al-Atrash G, Molldrem J, Futreal PA, Shpall E, Goodell M, Garcia-Manero G, Takahashi K Author Correction: Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation. Nat Genet 57(9):2339, 2025. PMID: 40789920.
Editorials
- Kantarjian H, Tefferi A. Treatment of adult acute lymphoblastic leukemia-a therapeutic revolution in the making. Blood Cancer J 16(1), 2026. PMID: 42557243.
Book Chapters
- Kantarjian, HM, Jabbour, EJ, O'Brien, S. Chronic myelogenous leukemia, 83-97, 2024.
- Kantarjian H, Jabbour E, Cortes J. Chronic Lymphocytic Leukemia. In: Harrison's Principles of Internal Medicine. 21. McGraw-Hill, 818-828, 2022.
- Chew, S, Short, NJ, Kantarjian, HM, Jabbour, EJ. Management of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia, 219-233, 2021.
- Paul, S, Rausch, CR, Kantarjian, HM, Jabbour, EJ. Minimal or Measurable Residual Disease in Acute Lymphoblastic Leukemia. In: Hematologic Malignancies. Springer Science Business Media Deutschland GmbH, 205-218, 2021.
- Jammal, N, Chew, S, Ravandi-Kashani, F, Kantarjian, HM, Jabbour, EJ. Management of Relapsed/Refractory Acute Myeloid Leukemia. In: Acute Leukemias. II. Springer International Publishing, 89-109, 2021.
- Mackey, MC, Chew, S, Kantarjian, HM, Jabbour, EJ. Frontline Therapy of Newly Diagnosed Acute Lymphoblastic Leukemia. In: Acute Leukemias. II. Springer International Publishing, 169-184, 2021.
- Lovell, A, Jabbour, EJ, Cortes, JE, Kantarjian, HM. CML Therapy, 61-76, 2021.
- Lovell A, Jabbour E, Cortes J, Kantarjian H. CML Therayp: A Focus on Second-and Third-Generation Tyrosine Kinase Inhibitors. In: Chronic Myeloid Leukemia. Second. Springer Nature Switzerland AG, 61-76, 2021.
- Jammal N, Chew S, Ravandi F, et al. Management of Relapsed/Refractory Acute Myeloid Leukemia. In: Acute Leukemias. 2. Springer International Publishing, 89-109, 2020.
- Mackey M, Chew S, Kantarjian H, et al. Frontline Therapy of Newly Diagnosed Acute Lymphoblastic Leukemia. In: Acute Leukemias. 2. Springer International Publishing, 157-167, 2020.
- Shilpa P, Rausch C, Kantarjian H, et al. Minimal or Measurable Residual Disease in Acxute Lymphoblastic Leukemia. In: Acute Leukemias. 2. Springer International Publishing, 205-218, 2020.
- Chew S, Short N, Kantarjian H, et al. Management of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. In: Acute Leukemias. 2. Springer International Publishing, 219-233, 2020.
- Kantarjian H, Cortes J. Chronic Myeloid Leukemia. In: Abeloff's Clinical Oncology. Sixth. Elsevier, 1836-1849, 2019.
- Kantarjian H, Jabbour E. Incorporating Immunotherapy Into the Treatment Strategies of B-Cell Adult Acute Lymphoblastic Leukemia: The Role of Blinatumomab and Inotuzumab Ozogamicin. In: Am Soc Clin Oncol Educ Book. 38. ASCO, 574-578, 2018.
- Kantarjian H, Cortes J. Chronic Myeloid Leukemia. In: Harrison's Principles of Internal Medicine. 20th. McGraw-Hill, 748-757, 2018.
- Cortes J, Silver R, Kantarjian H. Chronic Myeloid Leukemia. In: Holland-Frei Cancer Medicine. 9. John Wiley & Sons, Inc, 1571-1579, 2017.
- Jain N, Faderl S, Kantarjian H, O'Brien S. Acute Lymphoblastic Leukemia. In: Holland-Frei Cancer Medicine. 9. John Wiley & Sons, Inc, 1581-1593, 2017.
- Masarova L, Kantarjian H, Garcia-Manero G, Ravandi F, Sharma P, Daver N. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML. In: Advances in Experimental Medicine and Biology-Immunotherapy. Springer International Publishing AG, 73-95, 2017.
Books (edited and written)
- Kantarjian H, Elias. Harrison's Principles of Internal Medicine, 22nd Edition. Ed(s) 22. McGraw Hill, 2025.
- Kantarjian H, Wolff RA, Rieber AG. The MD Anderson Manual of Medical Oncology, Fourth Edition. Ed(s) 4th. McGraw-Hill, 2022.
- Faderl S, Kantarjian H, Estey E, et al. Acute Leukemias. Ed(s) 2. Springer International Publishing, 2020.
- Kantarjian HM, Editors WR. The MD Anderson Manual of Medical Oncology. Ed(s) 3rd. McGraw-Hill Education, 2016.
- Jabbour E, Kantarjian H, Cortes J, O'Brien S, Faderl S. Management of Hematologic Malignancies. Ed(s) 1st. Cambridge University Press, 2011.
- Kantarjian H, Wolff R, Editors KC. MD Anderson Manual of Medical Oncology. Ed(s) 2nd Edition. McGraw Hill Professional, 2011.
- Zeidan A, Wetzler M, Fletcher A, Whittle A, Bowen D, Koeppen H, Bueso-Ramos C, Konoplev S, Albitar M, Schafer E, Small D. Leukemias: Principles and Practice of Therapy. Ed(s) 1st. Wiley-Blackwell, 2010.
- Kantarjian H, Wolff R, Editors KC. MD Anderson Manual of Medical Oncology. Ed(s) 1st Edition. McGraw Hill Professional, 2006.
- Kantarjian H, Talpaz M. Hematology/Oncology clinics of North America Chronic Myelogenous Leukemia. . (www.TheClinics.com) . W. B. Saunders Company, a Division of Elsevier Inc, 2004.
- Kantarjian, HM, Hoelzer, Dieter, Larson. Hematology/Oncology Clinics of North America Advances in the Treatment of Adult Acute Lymphocytic Leukemia, Part II. , 2001.
- Kantarjian, HM, Hoelzer, Dieter, Larson. Hematology/Oncology Clinics of North America. Advances in the Treatment of Adult Acute Lymphocytic Leukemia, Part I. , 2000.
- Talpaz, Moshe, Kantarjian Hagop M. Medical Management of Chronic Myelogenous Leukemia. Marcel Dekker, Inc, 1999.
- Kantarjian, HM, Talpaz M. Treatment of Chronic Myelogenous Leukemia. Marcel Dekker, Inc, 1998.
- Freireich, Emil J, Kantarjian Hagop M. Molecular Genetics and Therapy in Leukemia. . Kluwer Academic Publishers, 1996.
- Freireich, Emil J, Kantarjian Hagop M. Leukemia: Advances in Research and Treatment. . Kluwer Academic Publishers, 1993.
- Kantarjian H Talpaz M. Treatment of Chronic Myelogenous Leukemia. . Marcel Dekker, Inc, 1991.
Letters to the Editor
- Jabbour E, Goulart H, Sasaki K, Rausch CR, Jain N, Kadia TM, DiNardo C, Daver N, Pemmaraju N, Ravandi F, Montalban-Bravo G, Garcia-Manero G, Hammond D, Swaminathan M, Hachem M, Khouri R, Ohanian M, Garris R, Short NJ, Kantarjian HM. Hyper-CVAD Versus Hyper-CVAD Plus Blinatumomab With or Without Inotuzumab Ozogamicin for Adult Patients With Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity-Score Analysis. Am J Hematol 101: 1729-1736, 2026.
- Chien KS, Li Z, Lanino L, Ali NA, Urrutia S, Bataller A, Kanagal-Shamanna R, Loghavi S, Lyu Y, Abdelhakeem A, Abuasab T, Almanza E, Ricos GG, Bazinet A, Campagna A, Maggioni G, Padron E, Xie Z, Montalban-Bravo G, Short NJ, Jabbour EJ, Kadia TM, Ravandi F, Borthakur G, DiNardo CD, Hammond D, Swaminathan M, Sasaki K, Dong XQ, Pierce SA, Sallman D, Kantarjian HM, Della Porta MG, Garcia-Manero G, Komrokji R. Performance of molecular scoring systems in hypomethylating agent-treated myelodysplastic neoplasms. Leukemia 40: 841-844, 2026.
- Marvin-Peek J, Kantarjian H, Jen WY, Daver N, Short N, Borthakur G, Bazinet A, Maiti A, Abbas H, Yilmaz M, Issa G, Macfarland M, Alvarado Y, Garcia-Manero G, Alousi A, Popat U, Shpall E, Ravandi F, DiNardo C, Kadia TM. Evaluating the Impact of Fewer Frontline Intensive Chemotherapy Plus Venetoclax Consolidation Cycles on Outcomes in AML. Am J Hematol 101: 917-922, 2026.
- Kantarjian H. Cytomolecular Mechanisms of Relapse and Post-Relapse Outcomes After Frontline FLT3 Inhibitor-Based Therapy in FLT3-Mutated AML. American journal of hematology 100: 2155-2159, 2025.
- Jen WY, Loghavi S, Bazinet A, Bataller A, Bouligny I, Daver NG, Issa GC, Arani N, Almanza Huante E, Maiti A, Montalban-Bravo G, Borthakur G, Short NJ, Pierce S, Jabbour E, Garcia-Manero G, Ravandi F, Kantarjian HM, DiNardo CD, Kadia TM. Outcomes and Patterns of Relapse of NPM1 Mutated Acute Myeloid Leukemia Treated With Venetoclax Based Therapies. Am J Hematol 100: 2118-2122, 2025.
- Senapati J, Garcia-Manero G, DiNardo CD, Deshmukh I, Borthakur G, Kadia TM, Jabbour E, Short NJ, Abbas HA, Pemmaraju N, Jain N, Haddad FG, Issa GC, Maiti A, Shpall E, Popat U, Loghavi S, Tang G, Yilmaz M, Alvarado Y, Montalban-Bravo G, Ravandi F, Kantarjian HM, Daver NG. Barriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemia. Bone Marrow Transplant 60: 910-913, 2025.
- Swaminathan M, DiNardo CD, Maiti A, Pemmaraju N, Ohanian M, Daver NG, Garcia-Manero G, Issa GC, Borthakur G, Ravandi F, Montalban-Bravo G, Kadia TM, Alvarado Y, Jabbour EJ, Short NJ, Wierda WG, Jain N, Kornblau SM, Masarova L, Pierce SA, Qiao W, Ning J, Kantarjian H, Konopleva MY. VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase 2 trial. Blood Cancer J 15: 52, 2025.
- Kawedia JD, Rausch CR, Liu X, Qiao W, Dinardo CD, Daver N, Borthakur G, Pemmaraju N, Reville P, Kontoyiannis DP, Short N, Konopleva M, Jabbour E, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Prospective Pharmacokinetic Evaluation of Venetoclax in AML Supports Re-Evaluation of Recommended Dose Adjustments With Azole Antifungals. Am J Hematol 100: 740-743, 2025.
Patents
- Zingaro R, Freireich E, Duzkale H, Kantarjian H, Verstovsek S, Sotelo-Lerma M. S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer. Patent Number: 6,995,188.
- Giles F, Kantarjian H, Jolivet J. Pharmaceutical combination for the treatment of cancer. Patent Number: 10/104,067/6,800,639.
- Zingaro R, Freireich E, Duzkale H, Kantarjian H, Verstovsek S, Sotelo-Lerma M. S-dimethylarsino-thiosuccinic acid S-dimethylarsino-2-thiobenzoic acid S-(dimethylarsino) glutathione as treatments for cancer. Patent Number: 7,619,000.
- Zingaro R, Freireich E, Duzkale H, Kantarjian H, Verstovsek S, Sotelo-Lerma M. S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer. Patent Number: 6,911,471.
- Albitar M, Estey E, Kantarjian H, Giles F, Keating M. Using plasma proteomic pattern for diagnosis, classification, prediction of response to therapy and clinical behavior, stratification of therapy, and monitoring disease in hematologic malignancies. Patent Number: 60563873/7,622,306.
- Zingaro R, Duzkale H, Freireich E, Kantarjian H, Sotelo-Lerma M, Verstovsek S, Gao M. Compounds and methods for the treatment of cancer. Patent Number: 7,405,314.
- Jolivet J, Giles F, Kantarjian H. Methods of treating leukemia. Patent Number: 10/286,960/6,645,972.
Patient Reviews
CV information above last modified August 30, 2026
MD Anderson Leukemia Chairman Hagop Kantarjian, M.D, with a colleague.
Hagop Kantarjian, M.D., with one of his paintings.
Hagop Kantarjian, M.D., chairman of MD Anderson's Leukemia department.